Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2014


Advances and Progress in Drug Design

17 Feb 2014 - 18 Feb 2014 - London, UK



Bookmark and Share


SPONSORED BY CHEMICAL COMPUTING GROUP

SMi are proud to present the 13th annual Advances and Progress in Drug Design conference, convening in Central London on Monday 17 and Tuesday 18 February 2014. This exciting event will focus on new approaches and will offer attendees the chance to hear from leading industry experts on lead optimisation strategies, SBDD and FBDD. 

Past events have received positive feedback from the industry including ‘Well selected talks, stimulating atmosphere’ – Sanofi, ‘Very good interactive meeting, overall excellent’ – Pfizer and ‘a very good meeting – right number of people’ - AstraZeneca

Advances and Progress in Drug Design Conference will build on the success of our previous events and bring together a unique mix of senior executives from all over industry and academia and will be an unrivalled forum for problem-solving discussion and debate. 

Benefits of Attending:

Understand pharma's current and future drug design strategies and highlight the challenges the industry is currently facing

Explore the latest approaches in structure-based drug design

Evaluate lead optimisation strategies

Consider the latest in fragment based drug discovery as the future of drug design

Linking HTS and FBDD - examining alternative approaches in drug discovery

Participate in two post conference interactive workshops hosted by Vernalis on New Approaches in ‘Structure Based Design’, and the 2nd hosted by The Research Network on ‘Chemically Modified Biologicals’

Ample opportunity for peer to peer networking with two morning coffee breaks, two networking lunches, two afternoon tea sessions and a networking drinks reception hosted by Chemical Computing Group on end of day one.

Key Speakers for 2014

John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer

Sudharsan Sridharan, Scientist, MedImmune

Tom Heightman, Senior Director, Astex Pharmaceuticals

Amaury Ernesto Fernandez-Montalvan, Lab Head, High Throughput Screening, Bayer HealthCare Pharmaceuticals

Karl-Heinz Baringhaus, Head of R&D, Sanofi-Aventis

Andreas Kuglstatter, Head of Protein Crystallography, Roche Chemische Unternehmungen AG

Dr Neil Press, Director, Novartis

Paul Labute, CEO, Chemical Computing Group

Andrea Bortolato, Senior Computational Chemistry, Heptares Therapeutics

Paul Brennan, Group Head/PI, Nuffield Department of Medicine

For further information visit us online at www.drug-design.co.uk

Alternatively, contact John Collins on +44 (0)20 7827 6734 or email jcollins@smi-online.co.uk




Further information
Scientific News
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!